4c7j: Difference between revisions
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[4c7j]] is a 4 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4C7J OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4C7J FirstGlance]. <br> | <table><tr><td colspan='2'>[[4c7j]] is a 4 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4C7J OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4C7J FirstGlance]. <br> | ||
</td></tr><tr><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=4YQ:4-CYCLOPROPYL-2-(2-HYDROXYETHYLOXY)-N-[(1S,3R)-5-OXIDANYL-2-ADAMANTYL]-1,3-THIAZOLE-5-CARBOXAMIDE'>4YQ</scene>, <scene name='pdbligand=NAP:NADP+NICOTINAMIDE-ADENINE-DINUCLEOTIDE+PHOSPHATE'>NAP</scene>< | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=4YQ:4-CYCLOPROPYL-2-(2-HYDROXYETHYLOXY)-N-[(1S,3R)-5-OXIDANYL-2-ADAMANTYL]-1,3-THIAZOLE-5-CARBOXAMIDE'>4YQ</scene>, <scene name='pdbligand=NAP:NADP+NICOTINAMIDE-ADENINE-DINUCLEOTIDE+PHOSPHATE'>NAP</scene></td></tr> | ||
<tr><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4c7k|4c7k]]</td></tr> | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4c7k|4c7k]]</td></tr> | ||
<tr><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/11-beta-hydroxysteroid_dehydrogenase 11-beta-hydroxysteroid dehydrogenase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=1.1.1.146 1.1.1.146] </span></td></tr> | <tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/11-beta-hydroxysteroid_dehydrogenase 11-beta-hydroxysteroid dehydrogenase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=1.1.1.146 1.1.1.146] </span></td></tr> | ||
<tr><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4c7j FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4c7j OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4c7j RCSB], [http://www.ebi.ac.uk/pdbsum/4c7j PDBsum]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4c7j FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4c7j OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4c7j RCSB], [http://www.ebi.ac.uk/pdbsum/4c7j PDBsum]</span></td></tr> | ||
<table> | </table> | ||
== Disease == | == Disease == | ||
[[http://www.uniprot.org/uniprot/DHI1_HUMAN DHI1_HUMAN]] Defects in HSD11B1 are a cause of cortisone reductase deficiency (CRD) [MIM:[http://omim.org/entry/604931 604931]]. In CRD, activation of cortisone to cortisol does not occur, resulting in adrenocorticotropin-mediated androgen excess and a phenotype resembling polycystic ovary syndrome (PCOS). | [[http://www.uniprot.org/uniprot/DHI1_HUMAN DHI1_HUMAN]] Defects in HSD11B1 are a cause of cortisone reductase deficiency (CRD) [MIM:[http://omim.org/entry/604931 604931]]. In CRD, activation of cortisone to cortisol does not occur, resulting in adrenocorticotropin-mediated androgen excess and a phenotype resembling polycystic ovary syndrome (PCOS). | ||
| Line 25: | Line 25: | ||
</StructureSection> | </StructureSection> | ||
[[Category: 11-beta-hydroxysteroid dehydrogenase]] | [[Category: 11-beta-hydroxysteroid dehydrogenase]] | ||
[[Category: Boyd, S | [[Category: Boyd, S]] | ||
[[Category: Dossetter, A G | [[Category: Dossetter, A G]] | ||
[[Category: Goldberg, F W | [[Category: Goldberg, F W]] | ||
[[Category: Groombridge, S D | [[Category: Groombridge, S D]] | ||
[[Category: Gutierrez, P Morentin | [[Category: Gutierrez, P Morentin]] | ||
[[Category: Kemmitt, P D | [[Category: Kemmitt, P D]] | ||
[[Category: Robb, G R | [[Category: Robb, G R]] | ||
[[Category: Schoolmeester, J de | [[Category: Schoolmeester, J de]] | ||
[[Category: Scott, J S | [[Category: Scott, J S]] | ||
[[Category: Sjogren, T | [[Category: Sjogren, T]] | ||
[[Category: Swales, J G | [[Category: Swales, J G]] | ||
[[Category: Turnbull, A V | [[Category: Turnbull, A V]] | ||
[[Category: Wild, M J | [[Category: Wild, M J]] | ||
[[Category: Cns penetration]] | [[Category: Cns penetration]] | ||
[[Category: Oxidoreductase]] | [[Category: Oxidoreductase]] | ||
[[Category: Structure-based design]] | [[Category: Structure-based design]] | ||
Revision as of 17:28, 5 January 2015
11b-Hydroxysteroid Dehydrogenase Type I in complex with inhibitor11b-Hydroxysteroid Dehydrogenase Type I in complex with inhibitor
Structural highlights
Disease[DHI1_HUMAN] Defects in HSD11B1 are a cause of cortisone reductase deficiency (CRD) [MIM:604931]. In CRD, activation of cortisone to cortisol does not occur, resulting in adrenocorticotropin-mediated androgen excess and a phenotype resembling polycystic ovary syndrome (PCOS). Function[DHI1_HUMAN] Catalyzes reversibly the conversion of cortisol to the inactive metabolite cortisone. Catalyzes reversibly the conversion of 7-ketocholesterol to 7-beta-hydroxycholesterol. In intact cells, the reaction runs only in one direction, from 7-ketocholesterol to 7-beta-hydroxycholesterol (By similarity). Publication Abstract from PubMed11beta-Hydroxysteroid dehydrogenase type 1 (11beta-HSD1) has been widely considered by the pharmaceutical industry as a target to treat metabolic syndrome in type II diabetics. We hypothesized that central nervous system (CNS) penetration might be required to see efficacy. Starting from a previously reported pyrimidine compound, we removed hydrogen-bond donors to yield 3, which had modest CNS penetration. More significant progress was achieved by changing the core to give 40, which combines good potency and CNS penetration. Compound 40 was dosed to diet-induced obese (DIO) mice and gave excellent target engagement in the liver and high free exposures of drug, both peripherally and in the CNS. However, no body weight reduction or effects on glucose or insulin were observed in this model. Similar data were obtained with a structurally diverse thiazole compound 51. This work casts doubt on the hypothesis that localized tissue modulation of 11beta-HSD1 activity alleviates metabolic syndrome. Optimization of brain penetrant 11beta-hydroxysteroid dehydrogenase type I inhibitors and in vivo testing in diet-induced obese mice.,Goldberg FW, Dossetter AG, Scott JS, Robb GR, Boyd S, Groombridge SD, Kemmitt PD, Sjogren T, Gutierrez PM, deSchoolmeester J, Swales JG, Turnbull AV, Wild MJ J Med Chem. 2014 Feb 13;57(3):970-86. doi: 10.1021/jm4016729. Epub 2014 Jan 27. PMID:24422550[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
|
| ||||||||||||||||||||